The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.
 
Shengxiang Ren
No Relationships to Disclose
 
Jie Zhang
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Xiaoqian Mu
No Relationships to Disclose
 
Jianying Zhou
No Relationships to Disclose
 
Zhang Bao
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Yanjun Xu
No Relationships to Disclose
 
Yongqian Shu
No Relationships to Disclose
 
Renhua Guo
No Relationships to Disclose
 
Xiaoqing Liu
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Helong Zhang
No Relationships to Disclose
 
Lin Deng
No Relationships to Disclose
 
Ningqiang Ma
No Relationships to Disclose
 
Jianxing He
No Relationships to Disclose
 
Yalei Zhang
No Relationships to Disclose
 
Caicun Zhou
Honoraria - Boehringer Ingelheim; Hengrui Therapeutics; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical